8 results on '"Ippoliti, Chiara"'
Search Results
2. Rapid Detection of the Omicron (B.1.1.529) SARS-CoV-2 Variant Using a COVID-19 Diagnostic PCR Assay
- Author
-
Ippoliti, Chiara, primary, De Maio, Flavio, additional, Santarelli, Giulia, additional, Marchetti, Simona, additional, Vella, Antonietta, additional, Santangelo, Rosaria, additional, Sanguinetti, Maurizio, additional, and Posteraro, Brunella, additional
- Published
- 2022
- Full Text
- View/download PDF
3. Rapid Detection of the Omicron (B.1.1.529) SARS-CoV-2 Variant Using a COVID-19 Diagnostic PCR Assay
- Author
-
Ippoliti, Chiara, De Maio, Flavio, Santarelli, Giulia, Marchetti, Simona, Vella, Antonietta, Santangelo, Rosaria, Sanguinetti, Maurizio, Posteraro, Brunella, Ippoliti C., De Maio F., Santarelli G., Marchetti S., Vella A., Santangelo R. (ORCID:0000-0002-8056-218X), Sanguinetti M. (ORCID:0000-0002-9780-7059), Posteraro B. (ORCID:0000-0002-1663-7546), Ippoliti, Chiara, De Maio, Flavio, Santarelli, Giulia, Marchetti, Simona, Vella, Antonietta, Santangelo, Rosaria, Sanguinetti, Maurizio, Posteraro, Brunella, Ippoliti C., De Maio F., Santarelli G., Marchetti S., Vella A., Santangelo R. (ORCID:0000-0002-8056-218X), Sanguinetti M. (ORCID:0000-0002-9780-7059), and Posteraro B. (ORCID:0000-0002-1663-7546)
- Abstract
The Omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the last variant of concern (VOC) identified to date. Compared to whole-genome or gene-specific sequencing methods, reverse-transcription PCR assays may be a simpler approach to study VOCs. We used a point-of-care COVID-19 diagnostic PCR assay to detect the Omicron SARS-CoV-2 variant in the respiratory tract samples of COVID-19 patients who had tested positive for SARS-CoV-2 RNA between April 2021 and January 2022. Sequencing analyses had shown that 87 samples were positive for the Omicron variant and 43 samples were positive for a non-Omicron variant (Delta, 18 samples; Alpha, 13 samples; Gamma, 10 samples; Beta, 1 sample; or Epsilon, 1 sample). According to results by the PCR assay, whose primers anneal a nucleocapsid (N) gene region that comprises the E31/R32/S33 deletion (also termed the del31/33 mutation), we found that N gene target failure/dropout (i.e., a negative/low result) occurred in 86 (98.8%) of 87 Omicron variant-positive samples tested. These results were assessed in relation to those of the spike (S) gene, which expectedly, was detected in all (100%) 130 samples. A total of 43 (100%) of 43 Delta, Alpha, Gamma, Beta, or Epsilon variant-positive samples had a positive result with the N gene. Importantly, in 86 of 87 Omicron variant-positive samples, the del31/33 mutation was detected together with a P13L mutation, which was, instead, detected alone in the Omicron variant-positive sample that had a positive N-gene result. IMPORTANCE Rapid detection of the Omicron SARS-CoV-2 variant in patients’ respiratory tract samples may influence therapeutic choices, because this variant is known to escape from certain monoclonal antibodies. Our findings strengthen the importance of manufacturers’ efforts to improve the existing COVID-19 diagnostic PCR assays and/or to develop novel variant-specific PCR assays. Furthermore, our findings show that only a small fraction
- Published
- 2022
4. Two-Period Study Results from a Large Italian Hospital Laboratory Attesting SARS-CoV-2 Variant PCR Assay Evolution
- Author
-
Liotti, Flora Marzia, De Maio, Flavio, Ippoliti, Chiara, Santarelli, Giulia, Monzo, F. R., Sali, Michela, Santangelo, Rosaria, Ceccherini-Silberstein, F., Sanguinetti, Maurizio, Posteraro, Brunella, Liotti F. M., De Maio F., Ippoliti C., Santarelli G., Sali M. (ORCID:0000-0003-3609-2990), Santangelo R. (ORCID:0000-0002-8056-218X), Sanguinetti M. (ORCID:0000-0002-9780-7059), Posteraro B. (ORCID:0000-0002-1663-7546), Liotti, Flora Marzia, De Maio, Flavio, Ippoliti, Chiara, Santarelli, Giulia, Monzo, F. R., Sali, Michela, Santangelo, Rosaria, Ceccherini-Silberstein, F., Sanguinetti, Maurizio, Posteraro, Brunella, Liotti F. M., De Maio F., Ippoliti C., Santarelli G., Sali M. (ORCID:0000-0003-3609-2990), Santangelo R. (ORCID:0000-0002-8056-218X), Sanguinetti M. (ORCID:0000-0002-9780-7059), and Posteraro B. (ORCID:0000-0002-1663-7546)
- Abstract
In keeping with the evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the COVID-19 causative agent, PCR assays have been developed to rapidly detect SARS-CoV-2 variants, which have emerged since the first (Alpha) variant was identified. Based on specific assortment of SARS-CoV-2 spike-protein mutations (DH69/V70, E484K, N501Y, W152C, L452R, K417N, and K417T) among the major variants known to date, Seegene Allplex SARS-CoV-2 Variants I and Variants II assays have been available since a few months before the last (Omicron) variant became predominant. Using S gene next-generation sequencing (NGS) as the SARS-CoV-2 variant identification reference method, we assessed the results of SARS-CoV-2-positive nasopharyngeal swab samples from two testing periods, before (n = 288, using only Variants I) and after (n = 77, using both Variants I and Variants II) the appearance of Omicron. The Variants I assay allowed correct identification for Alpha (37/37), Beta/Gamma (28/ 30), or Delta (220/221) variant-positive samples. The combination of the Variants I and Variants II assays allowed correct identification for 61/77 Omicron variant-positive samples. While 16 samples had the K417N mutation undetected with the Variants II assay, 74/77 samples had both DH69/V70 and N501Y mutations detected with the Variants I assay. If considering only the results by the Variants I assay, 6 (2 Beta variant positive, 1 Delta variant positive, and 3 Omicron variant positive) of 365 samples tested in total provided incorrect identification. We showed that the Variants I assay alone might be more suitable than both the Variants I and Variants II assays to identify currently circulating SARS-CoV-2 variants. Inclusion of additional variant-specific mutations should be expected in the development of future assays.
- Published
- 2022
5. Diagnosis and Treatment of Bacterial Pneumonia in Critically Ill Patients with COVID-19 Using a Multiplex PCR Assay: A Large Italian Hospital’s Five-Month Experience
- Author
-
Posteraro, Brunella, primary, Cortazzo, Venere, additional, Liotti, Flora Marzia, additional, Menchinelli, Giulia, additional, Ippoliti, Chiara, additional, De Angelis, Giulia, additional, La Sorda, Marilena, additional, Capalbo, Gennaro, additional, Vargas, Joel, additional, Antonelli, Massimo, additional, Sanguinetti, Maurizio, additional, De Pascale, Gennaro, additional, and Spanu, Teresa, additional
- Published
- 2021
- Full Text
- View/download PDF
6. Diagnosis and Treatment of Bacterial Pneumonia in Critically Ill Patients with COVID-19 Using a Multiplex PCR Assay: A Large Italian Hospital’s Five-Month Experience
- Author
-
Posteraro, Brunella, Cortazzo, Venere, Liotti, Flora Marzia, Menchinelli, Giulia, Ippoliti, Chiara, De Angelis, Giulia, la Sorda, M., Capalbo, Gennaro, Vargas, Joel, Antonelli, Massimo, Sanguinetti, Maurizio, De Pascale, Gennaro, Spanu Pennestri, Teresa, Posteraro B. (ORCID:0000-0002-1663-7546), Cortazzo V., Liotti F. M., Menchinelli G., Ippoliti C., de Angelis G. (ORCID:0000-0002-7087-7399), Capalbo G., Vargas J., Antonelli M. (ORCID:0000-0003-3007-1670), Sanguinetti M. (ORCID:0000-0002-9780-7059), de Pascale G. (ORCID:0000-0002-8255-0676), Spanu T. (ORCID:0000-0003-1864-5184), Posteraro, Brunella, Cortazzo, Venere, Liotti, Flora Marzia, Menchinelli, Giulia, Ippoliti, Chiara, De Angelis, Giulia, la Sorda, M., Capalbo, Gennaro, Vargas, Joel, Antonelli, Massimo, Sanguinetti, Maurizio, De Pascale, Gennaro, Spanu Pennestri, Teresa, Posteraro B. (ORCID:0000-0002-1663-7546), Cortazzo V., Liotti F. M., Menchinelli G., Ippoliti C., de Angelis G. (ORCID:0000-0002-7087-7399), Capalbo G., Vargas J., Antonelli M. (ORCID:0000-0003-3007-1670), Sanguinetti M. (ORCID:0000-0002-9780-7059), de Pascale G. (ORCID:0000-0002-8255-0676), and Spanu T. (ORCID:0000-0003-1864-5184)
- Abstract
Bacterial pneumonia is a challenging coronavirus disease 2019 (COVID-19) complication for intensive care unit (ICU) clinicians. Upon its implementation, the FilmArray pneumonia plus (FA-PP) panel’s practicability for both the diagnosis and antimicrobial therapy management of bacterial pneumonia was assessed in ICU patients with COVID-19. Respiratory samples were collected from patients who were mechanically ventilated at the time bacterial etiology and antimicrobial resistance were determined using both standard-of-care (culture and antimicrobial susceptibility testing [AST]) and FA-PP panel testing methods. Changes to targeted and/or appropriate antimicrobial therapy were reviewed. We tested 212 samples from 150 patients suspected of bacterial pneumonia. Etiologically, 120 samples were positive by both methods, two samples were culture positive but FA-PP negative (i.e., negative for on-panel organisms), and 90 were negative by both methods. FA-PP detected no culture-growing organisms (mostly Staphylococcus aureus or Pseudomonas aeruginosa) in 19 of 120 samples or antimicrobial resistance genes in two culture-negative samples for S. aureus organisms. Fifty-nine (27.8%) of 212 samples were from empirically treated patients. Antibiotics were discontinued in 5 (33.3%) of 15 patients with FA-PP-negative samples and were escalated/deescalated in 39 (88.6%) of 44 patients with FA-PP-positive samples. Overall, antibiotics were initiated in 87 (72.5%) of 120 pneumonia episodes and were not administered in 80 (87.0%) of 92 nonpneumonia episodes. Antimicrobial-resistant organisms caused 78 (60.0%) of 120 episodes. Excluding 19 colistin-resistant Acinetobacter baumannii episodes, AST confirmed appropriate antibiotic receipt in 101 (84.2%) of 120 episodes for one or more FA-PP-detected organisms. Compared to standard-of-care testing, the FA-PP panel may be of great value in the management of COVID-19 patients at risk of developing bacterial pneumonia in the ICU. IMPORTANCE Sinc
- Published
- 2021
7. Outcomes of endovascular repair of abdominal aortic aneurysms in narrow aortic bifurcations using the ultra-low profile “INCRAFT” device: A retrospective multicenter study
- Author
-
Orrico, M., Ronchey, S., Alberti, V., Ippoliti, Chiara, Citoni, G., Tshomba, Yamume, Bartoli, S., Mangialardi, N., Ippoliti A., Tshomba Y. (ORCID:0000-0001-7304-7553), Orrico, M., Ronchey, S., Alberti, V., Ippoliti, Chiara, Citoni, G., Tshomba, Yamume, Bartoli, S., Mangialardi, N., Ippoliti A., and Tshomba Y. (ORCID:0000-0001-7304-7553)
- Abstract
Objective: Although the long-term results of endovascular aortic repair (EVAR) with low-profile devices in patients with hostile iliac anatomies have been published, there are no reported results specifically for narrow aortic bifurcations (NAB). This study investigated the outcomes of EVAR with the INCRAFT device in NAB (<16 mm). Methods: This multicenter retrospective study involved five vascular surgery centers. From November 2014 until June 2018, 127 patients were treated with the INCRAFT device. The patient population was divided into two groups based on aortic bifurcation diameter. They were designated as the (1) standard aortic bifurcation (SAB) group (>16 mm) and the (2) the NAB group (<16 mm). Primary end points were the differences between the two groups in terms of technical success, survival at 30 days, iliac limb patency, and reinterventions. Results: The SAB group included 96 patients and the NAB group included 31 patients. The mean aortic bifurcation diameter was 25.5 mm in the SAB group and 13.2 mm in the NAB group. It is noteworthy that, in the NAB group, 21.8% of patients had aortic bifurcations with focal calcific lesions (less than one-third of the circumferential length of the bifurcation) and 48.3% showed extensive calcifications (two-thirds of the circumferential length of the bifurcation), for 29.9% of the patients in the NAB group the aortic bifurcation had a circumferential highly calcific lesion (complete occlusion of the circumferential length of the bifurcation). Technical success was 98.9% in the SAB group and 96.7% in the NAB group (P =.1). The need for iliac component stenting was not significantly different between the groups (SAB 2.0% vs NAB 3.2%; P =.07). The 1-year survival was 97.9% and 96.7% in the SAB and NAB groups, respectively, with no aneurysm-related mortality. The mean follow-up was 18.4 months and 15.3 months in the SAB and NAB groups, respectively. The iliac primary patency was 98.9 % in the SAB group and 96.8%
- Published
- 2019
8. WHO targets elimination of TB in over 30 countries
- Author
-
Ippoliti Chiara
- Subjects
Internationality ,Communicable Disease Control ,Humans ,Tuberculosis ,Global Health ,World Health Organization - Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.